Vertex Pharmaceuticals Inc. ( (VRTX) ) has released its Q3 earnings. Here is a breakdown of the information Vertex Pharmaceuticals Inc.

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Vertex also reported a steady increase in its R&D and SG&A expenses, reflecting its aggressive investment in pipeline ...

Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals VRTX. And retail traders should ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

Vertex Pharmaceuticals beat third-quarter expectations on Monday. Though the company raised its sales outlook, Vertex stock was muted.

Shares of Vertex Pharmaceuticals Inc. VRTX rose 1.00% to $475.08 Wednesday, on what proved to be an all-around rough trading ...

Vertex's diverse pipeline, including Casgevy for SCD, suzetrigine for chronic pain, and the vanzacaftor triple for CF, positions it for growth despite launch challenges. Casgevy's complex ...

Nov 4 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF ...

Pinnacle Associates Ltd. reduced its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 44.4% in the ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its target price raised by research analysts at Scotiabank from ...

Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals (NASDAQ:VRTX). And retail traders should know. We noticed this today when the trades showed up on ...